Ipinzan (Metformin Hydrochloride, Vildagliptin)

Metformin decreases hepatic glucose production and enhances peripheral insulin sensitivity, reducing overall blood sugar. Vildagliptin inhibits the enzyme DPP‑4, leading to higher levels of incretin hormones (GLP‑1 and GIP) that stimulate glucose‑dependent insulin release and suppress glucagon, providing complementary glucose‑lowering effects.

The appropriate dose of Ipinzan is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycemic targets, and concomitant medications. Dosage adjustments are made to achieve optimal blood‑glucose control while minimizing adverse effects.

Safety of Ipinzan in pregnancy and lactation has not been fully established. It should only be used if the potential benefits outweigh the possible risks to the mother and fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To order Ipinzan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details and any necessary import documentation.

Ipinzan combines metformin, a first‑line biguanide, with vildagliptin, a DPP‑4 inhibitor. Compared with metformin alone, the addition of vildagliptin offers greater post‑prandial glucose reduction and a lower risk of hypoglycemia than sulfonylureas. It provides an alternative to other fixed‑dose combinations such as metformin/sitagliptin, with a similar efficacy profile.

Ipinzan tablets should be stored at room temperature, below 25 °C, in the original container. Protect the product from moisture, direct sunlight and excessive heat. Do not store in a refrigerator or freezer, and keep out of reach of children.

Ipinzan is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably with meals to reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare professional and not alter the dose without medical advice.

The most serious adverse events associated with Ipinzan include lactic acidosis, which is rare but life‑threatening, severe hypoglycemia (especially when combined with other glucose‑lowering agents), acute pancreatitis, and severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these symptoms occur.

Ipinzan is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), significant hepatic disease, known hypersensitivity to metformin, vildagliptin, or any excipients, and in those with a history of lactic acidosis. Caution is also advised for patients with unstable heart failure or uncontrolled infections.